News | January 01, 2026
HUTCHMED’s Fanregratinib gains priority review in China for aggressive liver cancer
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
The study met its primary endpoint with flying colors
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Subscribe To Our Newsletter & Stay Updated
